P78 | Usefulness of an ad hoc questionnaire (Acro-PREV) for the acromegaly diagnosis in general medical outpatient
L.F.S. Grasso1, S. Ippolito1, O. Romano1, C. Peirce1, M. Martino2, R. Giannettino1, M. Maione1, C. Sepe1, F. Coretti1, V. Nuzzo1 | 1UOSD Malattie Endocrine del Ricambio e della Nutrizione, Ospedale del Mare ASL Napoli 1, 2UOSD Disturbi del Comportamento Alimentare ASL Roma 1, Italy
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Authors
Background and Aim: Acromegaly (ACRO) is characterized by increased release of growth hormone and, consequently, insulin-like growth factor I (IGF1), most often by a pituitary adenoma. The estimated prevalence is 40-125 cases/million but targeted universal screening studies have found a higher prevalence (about 10 fold). The aim of the present study was to investigate the usefulness of Acro-PREV questionaire to diagnosis ACRO between patients attending general medical outpatient.
Methods: The Acro-PREV investigate the main symptoms, physical changes and comorbities of ACRO. A self-administered questionnaire was provided to patients attending general medical outpatient. IGFI was measured in patients with ≥1 acral symptom/ physical changes and ≥2 comorbidities.
Results: Of the 200 patients enrolled, 54 patients (27%) were tested for IGF1, 1 case of ACRO were diagnosed. A male patient of 54 year old were diagnosed of acromegaly due to a pituitary macroadenoma GH-secreting.
Conclusions: In conclusion ACRO-PREV could be an useful tool for ACRO diagnosis, however further studies are needed on larger populations.
Altmetrics
Downloads
Citations
How to Cite
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.